Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed advanced solid tumor

- Refractory to conventional treatment or for which no conventional therapy exists

- Disease assessable by DCE-MRI and should be of a size that can be adequately assessed
by these techniques

- No known primary brain tumors or brain metastases

PATIENT CHARACTERISTICS:

- WHO performance status 0-1

- Life expectancy ≥ 12 weeks

- Hemoglobin ≥ 9.0 g/dL

- Platelet count ≥ 100 x 10^9/L

- Neutrophil count ≥ 1.5 x 10^9/L

- Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)

- ALT and AST ≤ 2.5 times ULN

- Creatinine clearance ≥ 50 mL/min (uncorrected value)

- Serum potassium and magnesium normal

- No proteinuria > grade 1 either on 24-hour urine or on 2 consecutive dipsticks taken
no less than 1 week apart

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception 4 weeks prior to, during, and for 6
months after completion of study therapy

- Not at high medical risk due to non-malignant systemic disease, including active
uncontrolled infection

- No serologically positive hepatitis B, hepatitis C, or HIV

- No concurrent congestive heart failure or prior NYHA class III-IV cardiac disease

- None of the following medical conditions:

- Angina (stable or severe, even if well controlled on medication)

- Myocardial infarction in the past 2 months by ECG

- Congestive cardiac failure

- Arrhythmias, including any condition associated with QTc prolongation (e.g.,
Lange-Neilson syndrome or Romano Ward syndrome)

- Evidence of ischemia

- QTc > 480 msec

- Other clinically significant abnormalities

- No uncontrolled hypertension (defined as BP consistently greater than 160/100 mm Hg
irrespective of medication)

- No other condition that, in the opinion of the investigator, would not make the
patient a good candidate for this clinical trial

- No pacemakers

- No metal fragments in the eyes or shrapnel or bullet injuries

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- Recovered from all prior treatments (except for alopecia or certain grade 1
toxicities which, in the opinion of the investigator and Cancer Research UK, should
not exclude the patient)

- At least 4 weeks since prior radiotherapy (except for palliative reasons), endocrine
therapy, immunotherapy, or chemotherapy (6 weeks for nitrosoureas and mitomycin C)

- At least 1 week since prior and no concurrent shellfish

- At least 6 weeks since prior major surgery (including thoracic and/or abdominal
surgery) and recovered

- Concurrent luteinizing-hormone releasing-hormone (LHRH) analogues allowed for
patients with castration-refractory prostate cancer provided the prostate-specific
antigen level is rising

- No prior heart or brain surgery

- No concurrent drug known to prolong the QTc interval

- No concurrent warfarin (1 mg for maintenance of a Hickman line is acceptable) or
heparin (flushing of arterial lines, if necessary, is acceptable)

- No concurrent naproxen (other NSAIDs are acceptable)

- No concurrent prophylactic use of antiemetics during the first treatment

- Domperidone and lorazepam must not be used as antiemetics

- No other concurrent anticancer therapy or investigational drugs

- Concurrent bisphosphonates allowed